Millipore Sigma Vibrant Logo

OP128 Anti-PLZF Mouse mAb (2A9)

This Anti-PLZF Mouse mAb (2A9) is validated for use in Gel Shift for the detection of PLZF.

Anti-PLZF Mouse mAb (2A9) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Promyelocytic Leukemia Zinc Finger

OP128
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Specifications Table

      Host
      M
      Description
      OverviewRecognizes the ~81 kDa PLZF in myelodysplastic cells treated with A23187 (Cat. No. 100105).

      This product has been discontinued.
      Catalogue NumberOP128
      Brand Family Calbiochem®
      SynonymsAnti-Promyelocytic Leukemia Zinc Finger
      References
      ReferencesYeyati, P.L., et al. 1999. Oncogene 18, 925.
      Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
      Li, J.Y., et al. 1997. Biol. Chem. 272, 22447.
      Licht, J.D., et al. 1996. Oncogene 12, 323.
      Avantaggiato, V., et al. 1995. J. Neurosci. 15, 4927.
      Cook, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 2249.
      Reid, A., et al. 1995. Blood 86, 4544.
      Chen, Z., et al. 1993. EMBO. J. 12,1161.
      Product Information
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
      Negative controlHEK293 or CV-1 cells
      Positive controlHL-60 or KG1 cells
      Preservative≤0.1% sodium azide
      Applications
      Application ReferencesOriginal Clone Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
      Key Applications Gel Shift
      Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Application NotesGel Shift (2 µg)
      Immunoblotting (2 µg/ml)
      Immunofluorescence (2 µg/ml)
      Immunoprecipitation (2 µg)
      Application CommentsPLZF, which migrates on SDS/PAGE as an 81 kDa protein, is expressed at low levels in HL60 cells but at higher levels in myelodysplastic cells treated with the calcium ionophore A23187. Immunoprecipitation of PLZF from total cell lysate using Cat. No. OP128 followed by immunoblotting with Cat. No. OP128 can be used to detect low level expression of PLZF. The PLZF protein can be detected in human erythroleukemia cells and in CD34+ progenitor cells in addition to HL60 and KG1 cells. Anti-PLZF will also detect the PLZF-RARα fusion protein expressed in APL cells carrying the t(11;17)(q23;q21) translocation but not the RARα-PLZF fusion protein generated by the reciprocal translocation.(J. Licht, per. comm.) Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena recombinant protein consisting of human PLZF fused to GST
      ImmunogenHuman
      Epitopewithin amino acids 100-200 of PLZF
      Clone2A9
      HostMouse
      IsotypeIgG2a
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      OP128 0

      Documentation

      Anti-PLZF Mouse mAb (2A9) Certificates of Analysis

      TitleLot Number
      OP128

      References

      Reference overview
      Yeyati, P.L., et al. 1999. Oncogene 18, 925.
      Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
      Li, J.Y., et al. 1997. Biol. Chem. 272, 22447.
      Licht, J.D., et al. 1996. Oncogene 12, 323.
      Avantaggiato, V., et al. 1995. J. Neurosci. 15, 4927.
      Cook, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 2249.
      Reid, A., et al. 1995. Blood 86, 4544.
      Chen, Z., et al. 1993. EMBO. J. 12,1161.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision02-July-2008 JSW
      SynonymsAnti-Promyelocytic Leukemia Zinc Finger
      ApplicationGel Shift (2 µg)
      Immunoblotting (2 µg/ml)
      Immunofluorescence (2 µg/ml)
      Immunoprecipitation (2 µg)
      DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes to myeloma cells (see application references). Recognizes the ~81 kDa PLZF protein.
      BackgroundThe promyelocytic leukemia zinc finger (PLZF) gene, first identified by its fusion with the RARα locus in a therapy resistant form of acute promyelocytic leukemia (APL) that is associated with the t(11;17)(q23;q21) translocation, encodes a 673 amino acid protein with nine Kruppel-like zinc fingers. PLZF is a sequence-specific DNA binding protein, highly conserved throughout vertebrate evolution, that is differentially expressed during embryogenesis and in adult tissues. The highest expression of PLZF occurs in multipotent, undifferentiated hematopietic progenitor cells and then declines following differentiation. PLZF is also expressed during development of the vertebrate hindbrain and may be critical for regulating boundary cell interactions. Recently, PLZF was shown to be a negative regulator of cell cycle progression capable of causing growth suppression leading to accumulation of cells in the G0/G1 stage of the cell cycle as well as a corresponding increased incidence of cells undergoing apoptosis. One target of PLZF is the cyclin A2 gene; PLZF can repress the cyclin A2 promoter and suppress growth while enforced expression of cyclin A2 reverts the growth suppressed phenotype of myeloid cells expressing PLZF. The RARα-PLZF fusion protein, generated in the t(11;17)(q23;q21)-form of APL, activates cyclin A2 transcription. Thus, inhibition of cyclin A2 expression may contribute to the growth suppressive properties of PLZF whereas deregulation of cyclin A2 by RARα-PLZF may represent an oncogenic mechanism of this chimeric protein. In addition to its role in hindbrain development, PLZF may contribute to the quiescent state of hematopoietic progenitor cells such that disruption of this activity in the therapy-resistant t(11;17)(q23;q21)-form of APL contributes to the drug-resistant character of this disease.
      HostMouse
      Immunogen speciesHuman
      Immunogena recombinant protein consisting of human PLZF fused to GST
      Epitopewithin amino acids 100-200 of PLZF
      Clone2A9
      IsotypeIgG2a
      Specieshuman, mouse, rat
      Positive controlHL-60 or KG1 cells
      Negative controlHEK293 or CV-1 cells
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsPLZF, which migrates on SDS/PAGE as an 81 kDa protein, is expressed at low levels in HL60 cells but at higher levels in myelodysplastic cells treated with the calcium ionophore A23187. Immunoprecipitation of PLZF from total cell lysate using Cat. No. OP128 followed by immunoblotting with Cat. No. OP128 can be used to detect low level expression of PLZF. The PLZF protein can be detected in human erythroleukemia cells and in CD34+ progenitor cells in addition to HL60 and KG1 cells. Anti-PLZF will also detect the PLZF-RARα fusion protein expressed in APL cells carrying the t(11;17)(q23;q21) translocation but not the RARα-PLZF fusion protein generated by the reciprocal translocation.(J. Licht, per. comm.) Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesYeyati, P.L., et al. 1999. Oncogene 18, 925.
      Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
      Li, J.Y., et al. 1997. Biol. Chem. 272, 22447.
      Licht, J.D., et al. 1996. Oncogene 12, 323.
      Avantaggiato, V., et al. 1995. J. Neurosci. 15, 4927.
      Cook, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 2249.
      Reid, A., et al. 1995. Blood 86, 4544.
      Chen, Z., et al. 1993. EMBO. J. 12,1161.
      Application referencesOriginal Clone Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.

      Related Products & Applications

      Related Products

      Catalog Number Description  
      OP128L Anti-PLZF Mouse mAb (2A9) Show Pricing & Availability

      Categories

      Life Science Research > Antibodies and Assays > Primary Antibodies